首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.
【24h】

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.

机译:四种潜在的生物标志物作为III期浆液性卵巢腺癌的预后因素。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein expressions for 7 potential biomarkers, to determine if it is possible to use them as prognostic factors. Genes selected from our previous microarray analysis (2006), CLU, ITGB3, TACC1, MUC5B, CAPG, PRAME and TROAP, were analyzed in 19 of the tumors with quantitative real-time polymerase chain reaction (QPCR). We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients. None of the other 3 genes were significantly differently expressed. The protein expressions of CLU, ITGB3, PRAME and CAPG were analyzed in 43 of the tumors with western blot for semiquantitative analysis. We established that the mRNA and protein expressions correlated and that all 4 proteins were significantly differently expressed. Further, immunohistochemistry (IHC) was used to localize the expression of the proteins in the tumor samples. According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas.
机译:卵巢癌患者的死亡率很高,并且可用的预后因素不足。生物标志物的使用可能有助于这些患者更好的预测和生存。我们旨在研究7种潜在生物标志物的基因和蛋白质表达,以确定是否有可能将其用作预后因素。使用定量实时聚合酶链反应(QPCR)在19个肿瘤中分析了从我们先前的微阵列分析(2006)中选择的基因CLU,ITGB3,TACC1,MUC5B,CAPG,PRAME和TROAP。我们发现,CLU和ITGB3在幸存者的肿瘤中表达更高,而PRAME和CAPG在死者的肿瘤中表达更高。其他3个基因均无明显差异表达。用western blot分析43例肿瘤中CLU,ITGB3,PRAME和CAPG的蛋白表达,并进行半定量分析。我们确定mRNA和蛋白质表达相互关联,并且所有4种蛋白质的表达均显着不同。此外,使用免疫组化(IHC)来定位肿瘤样品中蛋白质的表达。根据我们的结果,这四种生物标记物CLU,ITGB3,PRAME和CAPG可用作III期浆液性卵巢腺癌患者的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号